Repro Med Systems Inc (REPR)

[blue_skies]

Additional thoughts and observations on today's earnings release.
R&D and patent expenses both increased significantly.
R&D expenses YOY increased 190K (77K of that in Q4)
Payment for patents YOY increased a 100K
Look for new products to be released. Clinical trials provide a ground floor opportunity to match product to patient needs.

From the press release:
Growth in net sales in 2018 was driven by increased penetration of the PIDD market for SubQ Ig, some early adoption of the CIDP market and clinical trials which are a growing revenue source.

From the press release:
"Strategic Plan adopted with goals of $50 million net revenue, 70%+ Gross Margins and 20%+ annual organic revenue growth through 2022"

The company believes the $50 million dollarrevenue figure can be achieved via organic growth. (Primarily in the PIDD and CIDP markets?) The current revenues are 17.4 million. It would require a 287% increase to hit the 50 million figure. To go from the 17.4 revenue figure would require an annual compounded growth rate of 30%. Check my math.

I believe the company will be bought out or sold before the $50 million goal is achieved!!!